Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?

Journal of Neurochemistry

Volumn 115, Issue 4, 2010, Pages 829-844

  Farooqi, Nasr ^a   Gran, Bruno ^a   Constantinescu, Cris S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Disease modifying treatments; Experimental autoimmune encephalomyelitis; Glatiramer acetate; Interferon; Multiple sclerosis; Pre clinical studies

Indexed keywords

ALPHA INTERFERON; ANTIBODY; BETA INTERFERON; BETA1A INTERFERON; BIO 5192; CT 301; CYCLOPHOSPHAMIDE; EXTAVIA; FINGOLIMOD; FUMARIC ACID; FUMARIC ACID DERIVATIVE; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE; LAQUINIMOD; LEFLUNOMIDE; MINOCYCLINE; MITOXANTRONE; NATALIZUMAB; ROQUINIMEX; TERIFLUNOMIDE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4 ANTIBODY;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANTISENSE THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; EXPERIMENTAL MODEL; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTIRHEUMATIC AGENTS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; SPECIES SPECIFICITY;

ANIMALIA;

EID: 77958562204     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06982.x     Document Type: Review

References (115)

1. Abreu S. L. (1982) Suppression of experimental allergic encephalomyelitis by interferon. Immunol. Commun. 11, 1-7.
2. Abreu S. L. (1985) Interferon in experimental autoimmune encephalomyelitis (EAE): effects of exogeneous interferon on the antigen-enhanced adoptive transfer of EAE. Int. Arch. Allergy Appl. Immunol. 76, 302-307.
3. Abreu S. L., Tondreau J., Levine S. and Sowinski R. (1983) Inhibition of passive localized experimental allergic encephalomyelitis by interferon. Int. Arch. Allergy Appl. Immunol. 72, 30-33.
4. Abreu S. L., Thampoe I. and Kaplan P. (1986) Interferon in experimental autoimmune encephalomyelitis: intraventricular administration. J. Interferon Res. 6, 627-632.
5. Aharoni R., Teitelbaum D. and Arnon R. (1993) T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis. Eur. J. Immunol. 23, 17-25.
6. Aharoni R., Teitelbaum D., Sela M. and Arnon R. (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 94, 10821-10826.
7. Aharoni R., Teitelbaum D., Sela M. and Arnon R. (1998) Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J. Neuroimmunol. 91, 135-146.
8. Aharoni R., Arnon R. and Eilam R. (2005) Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci. 25, 8217-8228.
9. Balatoni B., Storch M. K., Swoboda E. M., Schonborn V., Koziel A., Lambrou G. N., Hiestand P. C., Weissert R. and Foster C. A. (2007) FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res. Bull. 74, 307-316.
10. Baxter A. G. (2007) The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 7, 904-912.
11. Begum-Haque S., Sharma A., Kasper I. R., Foureau D. M., Mielcarz D. W., Haque A. and Kasper L. H. (2008) Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 204, 58-65.
12. Bermel R. A. and Rudick R. A. (2007) Interferon-beta treatment for multiple sclerosis. Neurotherapeutics 4, 633-646.
13. Brinkmann V., Davis M. D., Heise C. E. et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453-21457.
14. Brocke S., Piercy C., Steinman L., Weissman I. L. and Veromaa T. (1999) Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl Acad. Sci. USA 96, 6896-6901.
15. Brod S. A. and Burns D. K. (1994) Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 44, 1144-1148.
16. Brod S. A. and Khan M. (1996) Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J. Autoimmun. 9, 11-20.
17. Brod S. A., Khan M., Kerman R. H. and Pappolla M. (1995a) Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 58, 61-69.
18. Brod S. A., Scott M., Burns D. K. and Phillips J. T. (1995b) Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J. Interferon Cytokine Res. 15, 115-122.
19. Brod S. A., Khan M., Nelson L. D., Decuir B., Malone M. and Henninger E. (2000) Adoptive transfer from interferon-alpha-fed mice is associated with inhibition of active experimental autoimmune encephalomyelitis by decreasing recipient tumor necrosis factor-alpha secretion. J. Immunother. 23, 235-245.
20. Brousil J. A., Roberts R. J. and Schlein A. L. (2006) Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann. Pharmacother. 40, 1814-1821.
21. Brunmark C., Runstrom A., Ohlsson L., Sparre B., Brodin T., Astrom M. and Hedlund G. (2002) The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130, 163-172.
22. Cabrera-Gomez J. A. and Lopez-Saura P. (1999) Alpha interferon in the treatment of multiple sclerosis. Update and experience in Cuba. Rev. Neurol. 28, 849-858.
23. Cannella B., Gaupp S., Tilton R. G. and Raine C. S. (2003) Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis. J. Neurosci. Res. 71, 407-416.
24. Cohen J. A., Barkhof F., Comi G. et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415.
25. Comi G., Pulizzi A., Rovaris M. et al. (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371, 2085-2092.
26. Compston A. and Coles A. (2008) Multiple sclerosis. Lancet 372, 1502-1517.
27. Croxford J. L., Triantaphyllopoulos K., Podhajcer O. L., Feldmann M., Baker D. and Chernajovsky Y. (1998) Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J. Immunol. 160, 5181-5187.
28. DerSimonian R. and Laird N. (1986) Meta-analysis in clinical trials. Control. Clin. Trials 7, 177-188.
29. Durelli L., Bongioanni M. R., Ferrero B. et al. (1996) Long term recombinant interferon alpha treatment in MS with special emphasis to side effects. Mult. Scler. 1, 366-371.
30. Farina C., Weber M. S., Meinl E., Wekerle H. and Hohlfeld R. (2005) Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 4, 567-575.
31. Fleming K. K., Bovaird J. A., Mosier M. C., Emerson M. R., LeVine S. M. and Marquis J. G. (2005) Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 170, 71-84.
32. Foster C. A., Howard L. M., Schweitzer A. et al. (2007) Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther. 323, 469-475.
33. Foster C. A., Mechtcheriakova D., Storch M. K. et al. (2009) FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 19, 254-266.
34. Frei K., Eugster H. P., Bopst M., Constantinescu C. S., Lavi E. and Fontana A. (1997) Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185, 2177-2182.
35. Fujino M., Funeshima N., Kitazawa Y., Kimura H., Amemiya H., Suzuki S. and Li X. K. (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 305, 70-77.
36. Fujita T., Inoue K., Yamamoto S., Ikumoto T., Sasaki S., Toyama R., Chiba K., Hoshino Y. and Okumoto T. (1994) Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiot. (Tokyo) 47, 208-215.
37. Gilgun-Sherki Y., Panet H., Holdengreber V., Mosberg-Galili R. and Offen D. (2003) Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci. Res. 47, 201-207.
38. Giovannoni G., Comi G., Cook S. et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416-426.
39. Giuliani F., Metz L. M., Wilson T., Fan Y., Bar-Or A. and Yong V. W. (2005) Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 158, 213-221.
40. Gold R., Linington C. and Lassmann H. (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129, 1953-1971.
41. Gran B. (2007) Experimental autoimmune encephalomyelitis, in Handbook of Neurochemistry and Molecular Neurobiology, Vol. 19 (Lajtha A., ed.), pp. 355-377. Springer, Heidelberg.
42. Guo B., Chang E. Y. and Cheng G. (2008) The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118, 1680-1690.
43. Hale G. (2001) Cd52 (Campath1). J. Biol. Regul. Homeost. Agents 15, 386-391.
44. Heremans H. and Biliau A. (2005) The role of interferons in EAE, in Experimental Models of Multiple Sclerosis (Lavi E. and Constantinescu C. S., eds), pp. 313-342. Springer, New York.
45. Hertz F. and Deghenghi R. (1985) Effect of rat and beta-human interferons on hyperacute experimental allergic encephalomyelitis in rats. Agents Actions 16, 397-403.
46. Hu Y., Turner M. J., Shields J., Gale M. S., Hutto E., Roberts B. L., Siders W. M. and Kaplan J. M. (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 128, 260-270.
47. Illes Z., Stern J. N., Reddy J. et al. (2004) Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells. Proc. Natl Acad. Sci. USA 101, 11749-11754.
48. Jagessar S. A., Kap Y. S., Heijmans N. et al. (2010) Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete freund adjuvant. J. Neuropathol. Exp. Neurol. 69, 372-385.
49. Jaini R., Hannaman D., Johnson J. M. et al. (2006) Gene-based intramuscular interferon-beta therapy for experimental autoimmune encephalomyelitis. Mol. Ther. 14, 416-422.
50. Jee Y., Piao W. H., Liu R., Bai X. F., Rhodes S., Rodebaugh R., Campagnolo D. I., Shi F. D. and Vollmer T. L. (2007) CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin. Immunol. 125, 34-42.
51. Kala M., Rhodes S. N., Piao W. H., Shi F. D., Campagnolo D. I. and Vollmer T. L. (2010) B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp. Neurol. 221, 136-145.
52. Kap Y. S., Laman J. D. and T Hart B. A. (2010) Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development. J. Neuroimmune Pharmacol. 5, 220-230.
53. Kappos L., Gold R., Miller D. H. et al. (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372, 1463-1472.
54. Kappos L., Radue E. W., O'Connor P. et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401.
55. Kataoka H., Sugahara K., Shimano K., Teshima K., Koyama M., Fukunari A. and Chiba K. (2005) FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell. Mol. Immunol. 2, 439-448.
56. Keith A. B., Arnon R., Teitelbaum D., Caspary E. A. and Wisniewski H. M. (1979) The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J. Neurol. Sci. 42, 267-274.
57. Kent S. J., Karlik S. J., Cannon C., Hines D. K., Yednock T. A., Fritz L. C. and Horner H. C. (1995) A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58, 1-10.
58. Knobler R. L., Panitch H. S., Braheny S. L. et al. (1984) Clinical trial of natural alpha interferon in multiple sclerosis. Ann. NY Acad. Sci. 436, 382-388.
59. Korn T., Magnus T., Toyka K. and Jung S. (2004) Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion. J. Leukoc. Biol. 76, 950-960.
60. Krishnamoorthy G. and Wekerle H. (2009) EAE: an immunologist's magic eye. Eur. J. Immunol. 39, 2031-2035.
61. Van Der Laan L. J., Van Der Goes A., Wauben M. H., Ruuls S. R., Dopp E. A., De Groot C. J., Kuijpers T. W., Elices M. J. and Dijkstra C. D. (2002) Beneficial effect of modified peptide inhibitor of alpha4 integrins on experimental allergic encephalomyelitis in Lewis rats. J. Neurosci. Res. 67, 191-199.
62. Lavi E. and Constantinescu C. (2005) Experimental Models of Multiple Sclerosis, pp. 901. Springer, New York.
63. Leger O. J., Yednock T. A., Tanner L. et al. (1997) Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum. Antibodies 8, 3-16.
64. Leist T. P. and Vermersch P. (2007) The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr. Med. Res. Opin. 23, 2667-2676.
65. Leone D. R., Giza K., Gill A. et al. (2003) An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J. Pharmacol. Exp. Ther. 305, 1150-1162.
66. Levine S. and Saltzman A. (1986) Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J. Neuroimmunol. 13, 175-181.
67. Lim S. Y. and Constantinescu C. S. (2010) Current and future disease-modifying therapies in multiple sclerosis. Int. J. Clin. Pract. 64, 637-650.
68. Lisak R. P., Zweiman B., Blanchard N. and Rorke L. B. (1983) Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J. Neurol. Sci. 62, 281-293.
69. Lublin F. D., Lavasa M., Viti C. and Knobler R. L. (1987) Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin. Immunol. Immunopathol. 45, 122-128.
70. Luca M. E., Visser L., Lucas C. J. and Nagelkerken L. (1999) IFN-beta modulates specific T cell responses in vitro but does not affect Experimental Autoimmune Encephalomyelitis in the SJL mouse. J. Neuroimmunol. 100, 190-196.
71. Makar T. K., Trisler D., Bever C. T. et al. (2008) Stem cell based delivery of IFN-beta reduces relapses in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 196, 67-81.
72. Mangano K., Nicoletti A., Patti F. et al. (2009) Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clin. Exp. Immunol. 159, 159-168.
73. Martin-Saavedra F. M., Flores N., Dorado B., Eguiluz C., Bravo B., Garcia-Merino A. and Ballester S. (2007) Beta-interferon unbalances the peripheral T cell proinflammatory response in experimental autoimmune encephalomyelitis. Mol. Immunol. 44, 3597-3607.
74. Van Der Meide P. H., De Labie M. C., Ruuls S. R., Groenestein R. J., Botman C. A., Olsson T. and Dijkstra C. D. (1998) Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J. Neuroimmunol. 84, 14-23.
75. Merrill J. E., Hanak S., Pu S. F., Liang J., Dang C., Iglesias-Bregna D., Harvey B., Zhu B. and McMonagle-Strucko K. (2009) Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J. Neurol. 256, 89-103.
76. Mix E., Meyer-Rienecker H. and Zettl U. K. (2008) Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J. Neurol. 255(Suppl 6), 7-14.
77. Moharregh-Khiabani D., Blank A., Skripuletz T., Miller E., Kotsiari A., Gudi V. and Stangel M. (2010) Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse. PLoS ONE 5, e11769.
78. Myers K. J., Witchell D. R., Graham M. J., Koo S., Butler M. and Condon T. P. (2005) Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis. J. Neuroimmunol. 160, 12-24.
79. Neuhaus O., Kieseier B. C. and Hartung H. P. (2006) Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol. Ther. 109, 198-209.
80. Niino M. and Sasaki H. (2010) Update on the treatment options for multiple sclerosis. Expert Rev. Clin. Immunol. 6, 77-88.
81. Noseworthy J. H., Lucchinetti C., Rodriguez M. and Weinshenker B. G. (2000) Multiple sclerosis. N. Engl. J. Med. 343, 938-952.
82. Papadopoulos D., Rundle J., Patel R. et al. (2010) FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J. Neurosci. Res. 88, 346-359.
83. Piraino P. S., Yednock T. A., Freedman S. B., Messersmith E. K., Pleiss M. A., Vandevert C., Thorsett E. D. and Karlik S. J. (2002) Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of alpha4 integrin. J. Neuroimmunol. 131, 147-159.
84. Prinz M., Schmidt H., Mildner A. et al. (2008) Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28, 675-686.
85. Rausch M., Hiestand P., Foster C. A., Baumann D. R., Cannet C. and Rudin M. (2004) Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 20, 16-24.
86. Ridge S. C., Sloboda A. E., McReynolds R. A., Levine S., Oronsky A. L. and Kerwar S. S. (1985) Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin. Immunol. Immunopathol. 35, 35-42.
87. Ruuls S. R., De Labie M. C., Weber K. S., Botman C. A., Groenestein R. J., Dijkstra C. D., Olsson T. and Van Der Meide P. H. (1996) The length of treatment determines whether IFN-beta prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J. Immunol. 157, 5721-5731.
88. Schaefer C., Hidalgo T. R., Cashion L. et al. (2006) Gene-based delivery of IFN-beta is efficacious in a murine model of experimental allergic encephalomyelitis. J. Interferon Cytokine Res. 26, 449-454.
89. Schilling S., Goelz S., Linker R., Luehder F. and Gold R. (2006) Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 145, 101-107.
90. Schimrigk S., Brune N., Hellwig K., Lukas C., Bellenberg B., Rieks M., Hoffmann V., Pohlau D. and Przuntek H. (2006) Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur. J. Neurol. 13, 604-610.
91. Soilu-Hanninen M., Roytta M., Salmi A. and Salonen R. (1997) Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J. Neuroimmunol. 72, 95-105.
92. Sriram S. and Steiner I. (2005) Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. 58, 939-945.
93. Steinman L. and Zamvil S. S. (2005) Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26, 565-571.
94. Steinman L. and Zamvil S. S. (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60, 12-21.
95. Stern J. N., Illes Z., Reddy J. et al. (2004) Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. Proc. Natl Acad. Sci. USA 101, 11743-11748.
96. Stern J. N., Keskin D. B., Zhang H., Lv H., Kato Z. and Strominger J. L. (2008) Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice. Proc. Natl Acad. Sci. USA 105, 5172-5176.
97. Stosic-Grujicic S., Ramic Z., Bumbasirevic V., Harhaji L. and Mostarica-Stojkovic M. (2004) Induction of experimental autoimmune encephalomyelitis in Dark Agouti rats without adjuvant. Clin. Exp. Immunol. 136, 49-55.
98. Teige I., Treschow A., Teige A., Mattsson R., Navikas V., Leanderson T., Holmdahl R. and Issazadeh-Navikas S. (2003) IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 170, 4776-4784.
99. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R. and Sela M. (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1, 242-248.
100. Teitelbaum D., Webb C., Meshorer A., Arnon R. and Sela M. (1973) Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur. J. Immunol. 3, 273-279.
101. Teitelbaum D., Webb C., Bree M., Meshorer A., Arnon R. and Sela M. (1974) Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin. Immunol. Immunopathol. 3, 256-262.
102. Teitelbaum D., Fridkis-Hareli M., Arnon R. and Sela M. (1996) Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64, 209-217.
103. Teitelbaum D., Arnon R. and Sela M. (1999) Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc. Natl Acad. Sci. USA 96, 3842-3847.
104. Teitelbaum D., Aharoni R., Klinger E., Kreitman R., Raymond E., Malley A., Shofti R., Sela M. and Arnon R. (2004) Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Ann. NY Acad. Sci. 1029, 239-249.
105. Theien B. E., Vanderlugt C. L., Eagar T. N., Nickerson-Nutter C., Nazareno R., Kuchroo V. K. and Miller S. D. (2001) Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107, 995-1006.
106. Theien B. E., Vanderlugt C. L., Nickerson-Nutter C., Cornebise M., Scott D. M., Perper S. J., Whalley E. T. and Miller S. D. (2003) Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 102, 4464-4471.
107. Tselis A. (2010) Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis. Curr. Opin. Investig. Drugs 11, 577-585.
108. Wallström E. and Olsson T. (2008) Rat models of Experimental Autoimmune Encephalomyelitis, in Sourcebook of Models for Biomedical Research (Michael Conn P., ed.), pp. 547-556. Humana Press, Totowa, New Jersey.
109. Webb M., Tham C. S., Lin F. F., Lariosa-Willingham K., Yu N., Hale J., Mandala S., Chun J. and Rao T. S. (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 153, 108-121.
110. Weiner H. L. and Cohen J. A. (2002) Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult. Scler. 8, 142-154.
111. Wender M., Michalak S. and Wygladalska-Jernas H. (2001) The effect of short-term treatment with interferon beta 1a on acute experimental allergic encephalomyelitis. Folia Neuropathol. 39, 91-93.
112. Yang J. S., Xu L. Y., Xiao B. G., Hedlund G. and Link H. (2004) Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 156, 3-9.
113. Yasuda C. L., Al-Sabbagh A., Oliveira E. C., Diaz-Bardales B. M., Garcia A. A. and Santos L. M. (1999) Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion. Immunol. Invest. 28, 115-126.
114. Yednock T. A., Cannon C., Fritz L. C., Sanchez-Madrid F., Steinman L. and Karin N. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356, 63-66.
115. Yu M., Nishiyama A., Trapp B. D. and Tuohy V. K. (1996) Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 64, 91-100.